Adopting a patient-centric approach provides a competitive edge in drug development, according to an April 14 statement by the chief medical officer at Parexel, a clinical research organization. The executive said that while 'patient centricity' is often discussed in the industry, it rarely translates into meaningful action.
The importance of this topic lies in its potential to improve clinical trial outcomes and accelerate the delivery of therapies to patients. By involving patients early and directly in research design and decision-making processes, companies can create studies that are more feasible for participants and more likely to succeed.
"Despite their compassion and expertise, I’ve seen most strategic decisions being made without ever speaking to the people we aim to serve," said the Parexel chief medical officer. They described how traditional approaches have kept scientific, medical, clinical, and business processes siloed from patient input. At Parexel, efforts now focus on using patient perspectives from the start—shaping study feasibility and protocol design—which benefits both patients and companies.
The article outlines several practical steps for increasing patient involvement: "Inviting patients into the process from the beginning by partnering with them on how to design clinical trials and seeking to understand their reasons for participation and the burdens they face." Patient advisors at Parexel ask if they would participate in proposed trials themselves—a question that sometimes leads researchers to reconsider visit frequency or cultural factors affecting participation.
According to the statement, adapting materials for clarity about procedures like genetic sampling or making certain procedures optional can encourage enrollment. The result is improved retention rates when patients see clear benefits rather than burdens from participating.
The chief medical officer emphasized that bringing together science, business interests, and patient care through collaboration creates better studies: "Bridging them through education, empathy and collaboration is how the best studies are run." Strategic partnerships with advocacy groups help drive faster study start-up times while reducing dropout rates. These changes allow new therapies to reach market sooner by avoiding costly mid-study amendments.
Reflecting on broader implications within drug development companies, they said: "They can continue to treat patient centricity as a buzzword or...reorient their work so that patients truly sit at the center." This includes giving patients permanent roles in decision-making processes as well as training employees about human impact alongside efficiency considerations. The article concludes that rebuilding research infrastructure around empathy will not only change industry practices but also expand what is possible for future patients.
